soul trial oral semaglutide cardiovascular outcomes 2024 2025 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Trial Scorecard: SOUL

Berberine is nature's way of potentially clearing the weeds: pulling out the overgrowth, restoring bal

GLP-1RAs reduce inflammatory biomarkers like IL-6, CRP, and ferritin in Covid-19 patients

Which one is the most effective

Professor Ania Jastreboff, MD, PhD Yale University provided an overview #ADA2026 of the TRIUMPH-1 trial for Retatrutide, the investigational triple G medicine from Eli Lilly and Company The unique trial design provided insights beyond #weightloss #obesity and also encompassed relevant endpoints for co-morbidities such as knee osteoarthritis and obstructive sleep apnea, two comorbidities highly sensitive to weight loss

They advise patients experiencing sudden vision loss or rapidly worsening eyesight to seek medical attention immediately